Jeffrey Dash, DO
Internal Medicine · Venice, FLNPI 1922189224
Payments from drug & device makers
Across 422 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$876
- GSK$802
- Novo Nordisk$799
- AstraZeneca$639
- Bayer$632
- Pfizer$628
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,234100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $876 |
| GSK | 69 | $802 |
| Novo Nordisk | 46 | $799 |
| AstraZeneca | 26 | $639 |
| Bayer | 27 | $632 |
| Pfizer | 35 | $628 |
| Amgen | 39 | $567 |
| Lilly USA, LLC | 22 | $392 |
| Astellas Pharma US Inc | 17 | $292 |
| Otsuka America Pharmaceutical, Inc. | 14 | $247 |
| Merck | 14 | $196 |
| Exact Sciences | 5 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $117 |
| Esperion Therapeutics, Inc. | 4 | $89 |
| Abbott | 4 | $84 |
| Amarin Pharma, Inc. | 4 | $78 |
| Biohaven Pharmaceuticals, Inc. | 3 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Novartis | 5 | $65 |
| IBSA Pharma Inc. | 3 | $51 |
| Currax Pharmaceuticals LLC | 3 | $40 |
| Therapeuticsmd, Inc. | 2 | $40 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Inogen, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Almatica Pharma LLC | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| PBG Puerto Rico LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,234 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $110,817 |
| EliquisApixaban | 105 | $107,643 |
| FarxigaDapagliflozin Propanediol | 74 | $74,169 |
| TrulicityDulaglutide | 46 | $51,968 |
| KerendiaFinerenone | 34 | $43,238 |
| XareltoRivaroxaban | 32 | $37,952 |
| OzempicSemaglutide | 18 | $27,851 |
| JardianceEmpagliflozin | 26 | $27,549 |
| RybelsusSemaglutide | 17 | $18,205 |
| MounjaroTirzepatide | 17 | $17,568 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,875 |
| MyrbetriqMirabegron | 11 | $12,771 |
| UbrelvyUbrogepant | 12 | $12,227 |
| EntrestoSacubitril/Valsartan | 12 | $9,814 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $802 | $132,732162 claims |
| PfizerEliquis, Paxlovid | $628 | $109,073123 claims |
| AstraZenecaFarxiga | $639 | $74,16974 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $392 | $69,53663 claims |
| Novo NordiskOzempic, Rybelsus | $799 | $46,05635 claims |
| BayerKerendia | $632 | $43,23834 claims |
| Astellas Pharma US IncMyrbetriq | $292 | $12,77111 claims |
| AbbVieUbrelvy | $876 | $12,22712 claims |
| NovartisEntresto | $65 | $9,81412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Venice
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.